If you find yourself facing a gap in Part D coverage during the year and you want to avoid significant out-of-pocket expenses, consider using generic drugs instead of costly brands, suggests Gail Shearer, director of Consumer Reports' Best Buy Drugs project.
"I think if people want to avoid the donut, even after they have enrolled in a plan, there is tremendous opportunity to save money by wiser decisions about what drugs to take," she says.
Say you need a relatively modest reduction in your cholesterol. You might consider switching to generic lovastatin from one of the brand-name statins. In the Sacramento, CA area, Consumer Reports found that seniors who switch from Lipitor to lovastatin can save from $279 to $737 a year, depending on the drug plan they choose.
"Even when you are enrolled in Medicare Part D, it's really worth having that conversation with your doctor," Shearer insists.
Navigating a drug plan's formulary, or list of covered drugs, once you are enrolled also poses a potential problem, Hayes adds. You may have chosen your plan because it covered a specific medicine. But there's nothing to prevent a plan from changing its formulary, as long as it gives 60 days notice.
People who are relatively sophisticated in cutting through bureaucracy and those who enlist the aide of a consumer advocate shouldn't have a problem getting their medications through the drug plans' exceptions and appeals processes, he says. Others will encounter difficulties.
"The neediest people, the oldest people, the sickest people will be least equipped to engage," he observes.
If you've enrolled in a drug plan for 2006 and decide during the year that you want to switch plans, you may have to wait. Generally speaking, seniors are allowed to change drug plans once a year, beginning November 15. There are exceptions, though, for example, if you move out of your drug plan's service area. So you may want to call 1-800-MEDICARE (1-800-633-4227) or visit www.medicare.gov.
Even if Medicare Part D is smooth sailing for you, there's a chance of disruption beginning in the fall of 2006. That's when analysts expect some drug plans to restructure, others to go out of business and new ones to enter the fray.
"It's still going to be complicated;" Hayes warns. "It's still going to be a whole new ballgame in the fall during re-upping time."